Rapid advice : treatment of tuberculosis in children
Loading...
Date
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
World Health Organization
Abstract
Description
iv, 19 p.
This Rapid Advice updates the World Health Organization guidance on the treatment of tuberculosis in children in response to new evidence on antituberculosis drug dosages and treatment regimens. Developed through systematic reviews, pharmacokinetic analyses, evidence summaries and expert consultation using WHO guideline development methods, the document provides evidence-based recommendations intended to support national tuberculosis control programmes in establishing high-quality treatment policies. It emphasizes a public health approach that seeks to optimize survival and quality of life while promoting access, equity, quality and sustainability in childhood tuberculosis care. The guidance presents revised recommendations on the dosages of first-line antituberculosis medicines, treatment regimens for pulmonary and extrapulmonary tuberculosis, management of children living in settings with high HIV prevalence or increased isoniazid resistance, treatment considerations for infants younger than three months, and the use of intermittent regimens, streptomycin and fluoroquinolones. It also describes the guideline revision process, dissemination and implementation strategies, and identifies priority research areas where additional evidence is needed to strengthen future recommendations for the management of tuberculosis in children.
This Rapid Advice updates the World Health Organization guidance on the treatment of tuberculosis in children in response to new evidence on antituberculosis drug dosages and treatment regimens. Developed through systematic reviews, pharmacokinetic analyses, evidence summaries and expert consultation using WHO guideline development methods, the document provides evidence-based recommendations intended to support national tuberculosis control programmes in establishing high-quality treatment policies. It emphasizes a public health approach that seeks to optimize survival and quality of life while promoting access, equity, quality and sustainability in childhood tuberculosis care. The guidance presents revised recommendations on the dosages of first-line antituberculosis medicines, treatment regimens for pulmonary and extrapulmonary tuberculosis, management of children living in settings with high HIV prevalence or increased isoniazid resistance, treatment considerations for infants younger than three months, and the use of intermittent regimens, streptomycin and fluoroquinolones. It also describes the guideline revision process, dissemination and implementation strategies, and identifies priority research areas where additional evidence is needed to strengthen future recommendations for the management of tuberculosis in children.